WhichPeps

PEG-MGF

PEGylated IGF-1 splice-variant-derived peptide concept

Musclegrowth-factor research…
Generic peptide vial illustrationPEG-MGF
Evidence levelHuman evidence
Human evidenceNone established
Regulatory statusNot FDA-approved

What you need to know in 20 seconds

What is it?PEGylated IGF-1 splice-variant-derived peptide concept
Research focusMuscle/growth-factor research claims
Human evidenceFDA reports no identified human exposure data for PEG-MGF drug products. Published human-cell studies concern MGF peptides rather than a validated PEG-MGF clinical product.
Regulatory statusNot FDA-approved; FDA highlights absence of human exposure and safety data for PEG-MGF.
Main limitationsHuman muscle-building/recovery efficacy, pharmacokinetics, optimal exposure, long-term safety or equivalence of commercial PEG-MGF to laboratory MGF peptides.
SafetyUnknown human safety; potential growth-factor and immunogenicity concerns.
i
FDA reports no identified human exposure data for PEG-MGF drug products. Published human-cell studies concern MGF peptides rather than a validated PEG-MGF clinical product.

What the evidence actually supports

  • Strong evidence-gap page: both the molecule mismatch and conflicting cell data should be visible.

What is not established / key limitations

  • ×Independent in-vitro replication questioned the claimed proliferative effect.

Selected study & evidence records

FDA evidence audit: PEG-MGF human exposure

2026 · Regulatory evidence review / no human exposure identified

FDA states it has not identified human exposure data for drug products containing PEG-MGF.

Study detail → Primary source ↗

MGF-E peptide in primary human muscle progenitor cells

2011 · In-vitro human-cell study

The study reported increased proliferation/fusion-related activity in some donor-age groups.

Study detail → Primary source ↗

MGF peptide replication study in myoblasts and muscle stem cells

2014 · In-vitro replication / null study

The investigators found no apparent proliferative or differentiation effect and questioned earlier claims for the peptide.

Study detail → Primary source ↗

Safety and unknowns

Unknown human safety; potential growth-factor and immunogenicity concerns.

Human safety is unknown; growth-factor pathway, PEGylation, immunogenicity, peptide impurities and uncertain product identity are relevant risks.

Technical details

Mechanism / biologyIntended to mimic/extend activity attributed to mechano-growth-factor peptide sequences; product definitions vary.
Route / formulation boundaryDo not confuse PEG-MGF with PEG-rHuMGDF (pegylated thrombopoietic growth factor), a different molecule in older literature.
Identity / data-quality noteHigh risk of literature-name confusion; exclude PEG-rHuMGDF papers.
Dosing evidence statusDosing research conclusion recorded. No verified human drug-exposure regimen identified; preclinical/community protocols should not be presented as human dosing evidence.
Identifiers & alternate namesPEGylated mechano growth factor

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.